<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01876082</url>
  </required_header>
  <id_info>
    <org_study_id>IB2011-03</org_study_id>
    <nct_id>NCT01876082</nct_id>
  </id_info>
  <brief_title>PAZOPANIB Efficacy and Tolerance in Desmoids Tumors</brief_title>
  <acronym>DESMOPAZ</acronym>
  <official_title>PAZOPANIB Efficacy and Tolerance in Desmoids Tumors : Phase 2 Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Bergonié</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Desmoids tumors are benign soft tissues tumors characterized by aggressiveness and potential&#xD;
      local recurrence. There is a female predominance with a sex ratio of 2/1 and median age at&#xD;
      diagnosis is about 30 years.&#xD;
&#xD;
      Only a complete surgical excision is recommended in desmoids tumors. Some forms of desmoid&#xD;
      tumors are recurrent and/or symptomatic and are not accessible to a conservative surgical&#xD;
      treatment. In these clinical situations, only a medical treatment may achieve tumor control&#xD;
      and quality of life maintenance. Place of systemic treatments in the management of desmoids&#xD;
      tumors is poorly evaluated. Regarding chemotherapy, methotrexate and vinblastine protocol is&#xD;
      actually the best evaluated combination, which allowed observing objective response rate&#xD;
      between 40 and 75%. Toxicity was mainly marked by the risk of haematological toxicity.&#xD;
&#xD;
      Pazopanib is an inhibitor of multi-target tyrosine kinase, in oral form, with selective type&#xD;
      receptors -1, -2 and -3 of VEGF receptors on the PDGFA and B, and c-Kit. It is currently&#xD;
      under clinical development in humans in the treatment of several tumor types.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II, randomized, multicenter, open label trial, evaluating efficacy and safety&#xD;
      of pazopanib versus a chemotherapy protocol combining methotrexate and vinblastine in&#xD;
      progressive and symptomatic desmoid tumors.&#xD;
&#xD;
      This study will include 72 patients in 15 centers of the French Sarcoma Group.&#xD;
&#xD;
      Patients will be treated according to therapeutic strategy allocated by randomization until&#xD;
      documented RECIST progression and for a maximum of 12 months :&#xD;
&#xD;
        -  Arm A = experimental strategy: daily oral administration of pazopanib.&#xD;
&#xD;
        -  Arm B = reference strategy: methotrexate-vinblastine.&#xD;
&#xD;
      In case of documented radiological progression (RECIST criteria):&#xD;
&#xD;
        -  Patients initially included in arm A will have the opportunity, as determined by the&#xD;
           investigator, to receive arm B treatment, or leave the study,&#xD;
&#xD;
        -  Patients initially included in arm B will have the opportunity, as determined by the&#xD;
           investigator, to receive arm A treatment, or leave the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 18, 2012</start_date>
  <completion_date type="Actual">September 2019</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Remaining Alive and Progression-free at 6 Months as Per RECIST 1.1 After the Day of Randomisation (6-month Non-progression Rate).</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of patients remaining alive and progression-free at 6 months as per RECIST 1.1 after the day of randomisation.&#xD;
Progression is defined using New Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study), or a unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Remaining Alive With Best Overall Response as Per RECIST v1.1.</measure>
    <time_frame>1 year</time_frame>
    <description>Best overall response is defined as the best response across all time points (RECIST v1.1). The best overall response is determined once all the data for the participant is known.&#xD;
Each patient has been assigned one of the following categories (RECIST 1.1): complete response (disappearance of all target lesions); partial response (&gt;=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters); progression (20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) and stable disease (nor CR, PR or progression).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Randomization to disease progression, or death due to any cause, whichever occurs first; until 2 years after the last patient randomized.</time_frame>
    <description>Progression-free survival (PFS) defined as the time from randomization to the first documented progression (as per RECIST v1.1) or death (due to any cause), whichever occurs first. Patients alive and progression free were censored at the date of last follow-up, death, or last patient contact. Progression is assessed as per RECIST v1.1. Progression-free survival is estimated as a function of time using Kaplan-Meier method.&#xD;
1- and 2-year PFS rates were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Randomization to disease progression, or death due to any cause, whichever occurs first; until 2 years after the last patient randomized.</time_frame>
    <description>Overall survival (OS) defined as the time from randomization to death (due to any cause). Patients alive were censored at the date of last follow-up or last patient contact. Overall survival was estimated as a function of time using Kaplan-Meier method.1- and 2-Year OS rates were reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Progressive Desmoids Tumors</condition>
  <arm_group>
    <arm_group_label>PAZOPANIB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pazopanib&#xD;
800 mg per day&#xD;
oral administration&#xD;
at least 1 hour before or 2 hours after a meal,&#xD;
until disease progression or for 12 months maximum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vinblastine and Methotrexate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAZOPANIB treatment</intervention_name>
    <description>Pazopanib&#xD;
800 mg per day&#xD;
oral administration&#xD;
at least 1 hour before or 2 hours after a meal,&#xD;
until disease progression or for 12 months maximum</description>
    <arm_group_label>PAZOPANIB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Comparator: Vinblastine and Methotrexate</intervention_name>
    <description>Active Comparator: Vinblastine and Methotrexate vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.</description>
    <arm_group_label>Vinblastine and Methotrexate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written consent;&#xD;
&#xD;
          2. Age ≥ 18 years;&#xD;
&#xD;
          3. ECOG ≤ 1;&#xD;
&#xD;
          4. Histologically confirmed desmoid tumor;&#xD;
&#xD;
          5. Disease progression before the patient's inclusion : completion of two similar imaging&#xD;
             obtained within 6 months apart (a tolerance of 6 weeks is accepted)&#xD;
&#xD;
          6. Measurable target lesion (RECIST criteria) ;&#xD;
&#xD;
          7. Left ventricular ejection fraction (MUGA or ECHO) within the normal;&#xD;
&#xD;
          8. Normal hematological, renal and liver functions :&#xD;
&#xD;
               1. Hemoglobin ≥ 9 g / dl; neutrophils ≥ 1.5 x 109 / l; platelets ≥ 100 x 109 / l;&#xD;
                  prothrombin time or INR1 ≤ 1.2 ULN or activated partial thromboplastin time ≤ 1.2&#xD;
                  ULN;&#xD;
&#xD;
               2. Amino alanine transferase and aspartate amino transferase ≤ 2.5 ULN;&#xD;
&#xD;
               3. Total bilirubin ≤ 1.5 ULN;&#xD;
&#xD;
               4. Creatinine ≤ 1.5 mg/dl or, if creatinine&gt; 1.5 mg/dl, Creatinine clearance ≥ 50&#xD;
                  m/min;&#xD;
&#xD;
               5. Urinary protein / urinary creatinine (Pu / Cu) &lt;1. If PU/Cu ≥ 1, patients must&#xD;
                  have a proteinuria below 1g/24 h&#xD;
&#xD;
          9. Women are eligible provided they:&#xD;
&#xD;
               1. Physiologically incapable of childbearing (hysterectomy, oophorectomy, bilateral&#xD;
                  tubal ligation, menopause).&#xD;
&#xD;
               2. Of childbearing age if they have had a negative pregnancy test in the week before&#xD;
                  the first dose of treatment.&#xD;
&#xD;
               3. Women of childbearing potential and men must agree to take an adequate method of&#xD;
                  contraception. Permitted contraceptive methods : IUD with a documented failure&#xD;
                  rate of 1% per year, Partner's vasectomy, complete sex abstinence (for 14 days&#xD;
                  before inclusion, the test period and after cessation of treatment according to&#xD;
                  the chemotherapy as described below), dual contraception, oral contraceptives.&#xD;
&#xD;
             Effective contraception must be implemented:&#xD;
&#xD;
               -  Up to 6 months after treatment with vinblastine&#xD;
&#xD;
               -  Up to 5 months after treatment with Methotrexate for men and up to 3 months after&#xD;
                  treatment with Methotrexate for women&#xD;
&#xD;
               -  For the duration of treatment with Pazopanib;&#xD;
&#xD;
         10. Affiliated to a social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Personal history of malignancy except:&#xD;
&#xD;
               1. Cervical intraepithelial neoplasia;&#xD;
&#xD;
               2. Skin basal cell carcinoma;&#xD;
&#xD;
               3. Treated localized prostate carcinoma with PSA &lt;1;&#xD;
&#xD;
               4. Neoplasia treated with curative intent, in remission for at least five years and&#xD;
                  considered at low risk of relapse.&#xD;
&#xD;
          2. Pretreatement by Pazopanib or Methotrexate - vinblastine;&#xD;
&#xD;
          3. Known allergy to Pazopanib, Methotrexate or vinblastine;&#xD;
&#xD;
          4. Histological sampling not available for review or biological study;&#xD;
&#xD;
          5. Clinical abnormalities which may increase the risk of gastric bleeding (not exhaustive&#xD;
             list);&#xD;
&#xD;
               1. Gastric tumor with known risk of bleeding;&#xD;
&#xD;
               2. Inflammatory bowel disease or other gastrointestinal disease may increase the&#xD;
                  risk of gastric perforation.&#xD;
&#xD;
          6. Pathologies that can lead to impaired intestinal absorption (not exhaustive):&#xD;
&#xD;
               1. Malabsorption;&#xD;
&#xD;
               2. Major resection of small intestine or stomach.&#xD;
&#xD;
          7. Active uncontrolled infectious disease;&#xD;
&#xD;
          8. Corrected QT interval&gt; 480 ms;&#xD;
&#xD;
          9. History of cardiovascular disease in the last 6 months:&#xD;
&#xD;
               1. Cardiac angioplasty;&#xD;
&#xD;
               2. Myocardial infarction;&#xD;
&#xD;
               3. Unstable angina;&#xD;
&#xD;
               4. Bypass surgery;&#xD;
&#xD;
               5. Symptomatic arterial disease.&#xD;
&#xD;
         10. Congestive heart failure grade II, III or IV according to the New York Hearth&#xD;
             Association (NYHA) classification;&#xD;
&#xD;
         11. Uncontrolled arterial hypertension (systolic blood pressure ≥ 140 mmHg or diastolic&#xD;
             blood pressure ≥ 90 mmHg);&#xD;
&#xD;
         12. History of stroke or transient ischemic attack, pulmonary embolism or deep vein&#xD;
             thrombosis not treated, within 6 months;&#xD;
&#xD;
         13. History of major surgery or trauma within 28 days prior the first day of treatment, or&#xD;
             presence of a wound, fracture or non-healed ulcer;&#xD;
&#xD;
         14. Evidence of active bleeding or bleeding tendency;&#xD;
&#xD;
         15. Known endobronchial lesions and / or infiltrative lesions of the large vessels lung;&#xD;
&#xD;
         16. History of hemoptysis of more than 2.5 ml in the eight weeks preceding the first day&#xD;
             of chemotherapy;&#xD;
&#xD;
         17. Pulmonary dysfunction, asthma, emphysema, chronic obstructive pulmonary bronchitis,&#xD;
             pneumonia, pneumothorax, pulmonary contusion, hemothorax, distress acute respiratory&#xD;
             syndrome, pulmonary fibrosis;&#xD;
&#xD;
         18. Severe renal dysfunction;&#xD;
&#xD;
         19. Severe hepatic dysfunction;&#xD;
&#xD;
         20. History of psoriasis, rheumatoid arthritis, alcoholism, illness or chronic liver&#xD;
             dysfunction;&#xD;
&#xD;
         21. Any pre-existing severe or unstable medical or psychiatric condition, or other&#xD;
             condition that may interfere with patient safety, the collection of its informed&#xD;
             consent or adherence to treatment;&#xD;
&#xD;
         22. Patient who refused or could not stop taking banned drugs for at least 14 days (or 5&#xD;
             half-lives of the drug) before the first day of start of chemotherapy and for the&#xD;
             duration of the study;&#xD;
&#xD;
         23. During cancer treatment:&#xD;
&#xD;
               1. Radiotherapy, surgery or tumor embolization within 14 days before the 1st dose of&#xD;
                  pazobanib (arm A) or chemotherapy methotrexate, vinblastine (arm B);&#xD;
&#xD;
               2. Chemotherapy, immunotherapy, biological treatment, experimental or hormone&#xD;
                  therapy within 14 days or 5 half-lives of medication before the first day of the&#xD;
                  pazopanib (arm A) or chemotherapy with methotrexate, vinblastine (arm B).&#xD;
&#xD;
         24. History of cancer treatment toxicity&gt; grade 1 and / or whose the intensity increases,&#xD;
             outside of alopecia.&#xD;
&#xD;
         25. Pregnancy and lactation&#xD;
&#xD;
         26. Concomitant treatment which can't be interrupted or replaced and which is not&#xD;
             indicated with methotrexate:&#xD;
&#xD;
               1. Probenecid (alone or associated with sulfamethoxazole),&#xD;
&#xD;
               2. Trimethoprim,&#xD;
&#xD;
               3. Acetylsalicylic acid (for methotrexate doses above 20 mg per week with the&#xD;
                  acetylsalicylic acid and used at doses analgesics or antipyretics (≥ 500 mg per&#xD;
                  dose and/or &lt;3 g per day)or anti-inflammatory (≥ 1 g per dose and / or &gt; 3 g per&#xD;
                  day),&#xD;
&#xD;
               4. Phenylbutazone,&#xD;
&#xD;
               5. Yellow fever vaccine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ITALIANO Antoine, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <state>Aquitaine</state>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.e-cancer.fr/Professionnels-de-sante/Le-registre-des-essais-cliniques/Le-registre-des-essais-cliniques</url>
    <description>Registre des essais cliniques de l'INCa</description>
  </link>
  <link>
    <url>https://www.bergonie.fr/essais_cliniques/</url>
    <description>Site internet du promoteur, l'Institut Bergonié</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 6, 2012</study_first_submitted>
  <study_first_submitted_qc>June 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2013</study_first_posted>
  <results_first_submitted>December 30, 2020</results_first_submitted>
  <results_first_submitted_qc>February 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 5, 2021</results_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Desmoids tumors</keyword>
  <keyword>Pazopanib</keyword>
  <keyword>Phase 2 clinical trial</keyword>
  <keyword>Cross over</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromatosis, Aggressive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 19, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT01876082/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PAZOPANIB</title>
          <description>Pazopanib&#xD;
800 mg per day&#xD;
oral administration&#xD;
at least 1 hour before or 2 hours after a meal,&#xD;
until disease progression or for 12 months maximum&#xD;
PAZOPANIB treatment: Pazopanib&#xD;
800 mg per day&#xD;
oral administration&#xD;
at least 1 hour before or 2 hours after a meal,&#xD;
until disease progression or for 12 months maximum</description>
        </group>
        <group group_id="P2">
          <title>Vinblastine and Methotrexate</title>
          <description>vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.&#xD;
Active Comparator: Vinblastine and Methotrexate: Active Comparator: Vinblastine and Methotrexate vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="22">2 patients did not start control treatment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>treatment interruption of more than 21 consecutive days observed in cycle 1</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PAZOPANIB</title>
          <description>Pazopanib&#xD;
800 mg per day&#xD;
oral administration&#xD;
at least 1 hour before or 2 hours after a meal,&#xD;
until disease progression or for 12 months maximum&#xD;
PAZOPANIB treatment: Pazopanib&#xD;
800 mg per day&#xD;
oral administration&#xD;
at least 1 hour before or 2 hours after a meal,&#xD;
until disease progression or for 12 months maximum</description>
        </group>
        <group group_id="B2">
          <title>Vinblastine and Methotrexate</title>
          <description>vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.&#xD;
Active Comparator: Vinblastine and Methotrexate: Active Comparator: Vinblastine and Methotrexate vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="48"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.5" lower_limit="30.6" upper_limit="56.0"/>
                    <measurement group_id="B2" value="42.5" lower_limit="30.5" upper_limit="54.0"/>
                    <measurement group_id="B3" value="39.8" lower_limit="30.6" upper_limit="54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="48"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="48"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Remaining Alive and Progression-free at 6 Months as Per RECIST 1.1 After the Day of Randomisation (6-month Non-progression Rate).</title>
        <description>Percentage of patients remaining alive and progression-free at 6 months as per RECIST 1.1 after the day of randomisation.&#xD;
Progression is defined using New Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study), or a unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions.</description>
        <time_frame>6 months</time_frame>
        <population>Population evaluable for efficacy included all patients who met eligibility criteria and had received at least one complete cycle or two incomplete cycles of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>PAZOPANIB</title>
            <description>Pazopanib&#xD;
800 mg per day&#xD;
oral administration&#xD;
at least 1 hour before or 2 hours after a meal,&#xD;
until disease progression or for 12 months maximum&#xD;
PAZOPANIB treatment: Pazopanib&#xD;
800 mg per day&#xD;
oral administration&#xD;
at least 1 hour before or 2 hours after a meal,&#xD;
until disease progression or for 12 months maximum</description>
          </group>
          <group group_id="O2">
            <title>Vinblastine and Methotrexate</title>
            <description>vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.&#xD;
Active Comparator: Vinblastine and Methotrexate: Active Comparator: Vinblastine and Methotrexate vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Remaining Alive and Progression-free at 6 Months as Per RECIST 1.1 After the Day of Randomisation (6-month Non-progression Rate).</title>
          <description>Percentage of patients remaining alive and progression-free at 6 months as per RECIST 1.1 after the day of randomisation.&#xD;
Progression is defined using New Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study), or a unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions.</description>
          <population>Population evaluable for efficacy included all patients who met eligibility criteria and had received at least one complete cycle or two incomplete cycles of treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.8" lower_limit="71.1" upper_limit="93.7"/>
                    <measurement group_id="O2" value="45.0" lower_limit="23.1" upper_limit="68.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Remaining Alive With Best Overall Response as Per RECIST v1.1.</title>
        <description>Best overall response is defined as the best response across all time points (RECIST v1.1). The best overall response is determined once all the data for the participant is known.&#xD;
Each patient has been assigned one of the following categories (RECIST 1.1): complete response (disappearance of all target lesions); partial response (&gt;=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters); progression (20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) and stable disease (nor CR, PR or progression).</description>
        <time_frame>1 year</time_frame>
        <population>Population evaluable for efficacy included all patients who met eligibility criteria and had received at least one complete cycle or two incomplete cycles of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>PAZOPANIB</title>
            <description>Pazopanib&#xD;
800 mg per day&#xD;
oral administration&#xD;
at least 1 hour before or 2 hours after a meal,&#xD;
until disease progression or for 12 months maximum&#xD;
PAZOPANIB treatment: Pazopanib&#xD;
800 mg per day&#xD;
oral administration&#xD;
at least 1 hour before or 2 hours after a meal,&#xD;
until disease progression or for 12 months maximum</description>
          </group>
          <group group_id="O2">
            <title>Vinblastine and Methotrexate</title>
            <description>vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.&#xD;
Active Comparator: Vinblastine and Methotrexate: Active Comparator: Vinblastine and Methotrexate vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Remaining Alive With Best Overall Response as Per RECIST v1.1.</title>
          <description>Best overall response is defined as the best response across all time points (RECIST v1.1). The best overall response is determined once all the data for the participant is known.&#xD;
Each patient has been assigned one of the following categories (RECIST 1.1): complete response (disappearance of all target lesions); partial response (&gt;=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters); progression (20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) and stable disease (nor CR, PR or progression).</description>
          <population>Population evaluable for efficacy included all patients who met eligibility criteria and had received at least one complete cycle or two incomplete cycles of treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.3" lower_limit="27.0" upper_limit="56.8"/>
                    <measurement group_id="O2" value="30.0" lower_limit="11.9" upper_limit="54.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.4" lower_limit="39.0" upper_limit="69.1"/>
                    <measurement group_id="O2" value="45.0" lower_limit="23.1" upper_limit="68.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="0.5" upper_limit="14.8"/>
                    <measurement group_id="O2" value="20.0" lower_limit="5.7" upper_limit="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inevaluable for response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="5.0" lower_limit="0.1" upper_limit="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>Progression-free survival (PFS) defined as the time from randomization to the first documented progression (as per RECIST v1.1) or death (due to any cause), whichever occurs first. Patients alive and progression free were censored at the date of last follow-up, death, or last patient contact. Progression is assessed as per RECIST v1.1. Progression-free survival is estimated as a function of time using Kaplan-Meier method.&#xD;
1- and 2-year PFS rates were reported.</description>
        <time_frame>Randomization to disease progression, or death due to any cause, whichever occurs first; until 2 years after the last patient randomized.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PAZOPANIB</title>
            <description>Pazopanib&#xD;
800 mg per day&#xD;
oral administration&#xD;
at least 1 hour before or 2 hours after a meal,&#xD;
until disease progression or for 12 months maximum&#xD;
PAZOPANIB treatment: Pazopanib&#xD;
800 mg per day&#xD;
oral administration&#xD;
at least 1 hour before or 2 hours after a meal,&#xD;
until disease progression or for 12 months maximum</description>
          </group>
          <group group_id="O2">
            <title>Vinblastine and Methotrexate</title>
            <description>vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.&#xD;
Active Comparator: Vinblastine and Methotrexate: Active Comparator: Vinblastine and Methotrexate vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Progression-free survival (PFS) defined as the time from randomization to the first documented progression (as per RECIST v1.1) or death (due to any cause), whichever occurs first. Patients alive and progression free were censored at the date of last follow-up, death, or last patient contact. Progression is assessed as per RECIST v1.1. Progression-free survival is estimated as a function of time using Kaplan-Meier method.&#xD;
1- and 2-year PFS rates were reported.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PFS rate at 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.8" lower_limit="70.7" upper_limit="92.4"/>
                    <measurement group_id="O2" value="68.6" lower_limit="43.0" upper_limit="84.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PFS rate at 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.2" lower_limit="49.6" upper_limit="77.0"/>
                    <measurement group_id="O2" value="68.6" lower_limit="43.0" upper_limit="84.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival (OS) defined as the time from randomization to death (due to any cause). Patients alive were censored at the date of last follow-up or last patient contact. Overall survival was estimated as a function of time using Kaplan-Meier method.1- and 2-Year OS rates were reported.</description>
        <time_frame>Randomization to disease progression, or death due to any cause, whichever occurs first; until 2 years after the last patient randomized.</time_frame>
        <population>Population evaluable for efficacy included all patients who met eligibility criteria and had received at least one complete cycle or two incomplete cycles of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>PAZOPANIB</title>
            <description>Pazopanib&#xD;
800 mg per day&#xD;
oral administration&#xD;
at least 1 hour before or 2 hours after a meal,&#xD;
until disease progression or for 12 months maximum&#xD;
PAZOPANIB treatment: Pazopanib&#xD;
800 mg per day&#xD;
oral administration&#xD;
at least 1 hour before or 2 hours after a meal,&#xD;
until disease progression or for 12 months maximum</description>
          </group>
          <group group_id="O2">
            <title>Vinblastine and Methotrexate</title>
            <description>vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.&#xD;
Active Comparator: Vinblastine and Methotrexate: Active Comparator: Vinblastine and Methotrexate vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival (OS) defined as the time from randomization to death (due to any cause). Patients alive were censored at the date of last follow-up or last patient contact. Overall survival was estimated as a function of time using Kaplan-Meier method.1- and 2-Year OS rates were reported.</description>
          <population>Population evaluable for efficacy included all patients who met eligibility criteria and had received at least one complete cycle or two incomplete cycles of treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OS rate at 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="NA" upper_limit="NA">Only 1 patient from arm A died after 1 year hence insufficient patient with event to calculate the confidence limits for the 1-year OS rate.</measurement>
                    <measurement group_id="O2" value="100.0" lower_limit="NA" upper_limit="NA">Only 1 patient from arm A died after 1 year hence insufficient patient with event to calculate the confidence limits for the 1-year OS rate.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OS rate at 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8" lower_limit="85.6" upper_limit="99.7"/>
                    <measurement group_id="O2" value="100.0" lower_limit="NA" upper_limit="NA">Only 1 patient from arm A died after 1 year hence insufficient patient with event to calculate the confidence limits for the 2-year OS rate.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PAZOPANIB</title>
          <description>Pazopanib&#xD;
800 mg per day&#xD;
oral administration&#xD;
at least 1 hour before or 2 hours after a meal,&#xD;
until disease progression or for 12 months maximum&#xD;
PAZOPANIB treatment: Pazopanib&#xD;
800 mg per day&#xD;
oral administration&#xD;
at least 1 hour before or 2 hours after a meal,&#xD;
until disease progression or for 12 months maximum</description>
        </group>
        <group group_id="E2">
          <title>Vinblastine and Methotrexate</title>
          <description>vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.&#xD;
Active Comparator: Vinblastine and Methotrexate: Active Comparator: Vinblastine and Methotrexate vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Blood and lymphatic system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Duodenal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Infusion site extravasation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Eye disorders - Other, specify</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="29" subjects_affected="16" subjects_at_risk="48"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="60" subjects_affected="37" subjects_at_risk="48"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="48"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="34" subjects_affected="26" subjects_at_risk="48"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="24" subjects_affected="15" subjects_at_risk="48"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="45" subjects_affected="40" subjects_at_risk="48"/>
                <counts group_id="E2" events="19" subjects_affected="15" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="48"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="48"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>GGT increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Investigations - Other, specify</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="48"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other, specify</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="48"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysesthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="32" subjects_affected="21" subjects_at_risk="48"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Psychiatric disorders - Other, specify</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine hemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysesthesia syndrome</sub_title>
                <counts group_id="E1" events="22" subjects_affected="16" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <counts group_id="E1" events="50" subjects_affected="36" subjects_at_risk="48"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Skin hypopigmentation</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="27" subjects_affected="22" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pr Antoine Italiano, coordinating investigator</name_or_title>
      <organization>Department of Medical Oncology, Institut bergonié</organization>
      <phone>05.47.30.60.88</phone>
      <email>a.italiano@bordeaux.unicancer.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

